Table of Contents What the WHOs New Guideline Says Why This Matters for Diabetes Care Clinical and Practical Considerations Looking Ahead: Diabetes Care and Chronic Obesity Management Conclusion FAQs What the WHOs New Guideline Says In December 2025, the World Health Organization released its first-ever guideline recommending GLP1 therapies for adults with obesity
The synergy between the two receptor pathways is present even at low doses, which is an argument for tirzepatide-based microdosing over semaglutide-based microdosing from a metabolic standpoint
Serious side effects of retatrutide are hypersensitivity reaction, pancreatitis, gallbladder issues, hypoglycemia, cardiovascular event, liver disorders, and renal issues, but they are rare
The exact reason for this is unclear, but may be because women are more likely to see a doctor about their melanoma at an earlier stage 20
Indian J Dermatol Venereol Leprol 83(3):312316